Dr. Richard L. Deming, MD

Dr. Deming practices at Select Specialty Hospital - Des Moines in Des Moines, Iowa, part of Select Medical Holdings.

Dr. Deming's NPI, 1255418059, was assigned on November 1, 2006. Dr. Deming graduated from Creighton University School of Medicine - Omaha in 1980. Dr. Deming's Iowa license number on file is MD-27058.

Dr. Deming's primary practice is Select Specialty Hospital - Des Moines, at 1111 6th Avenue, 4th Floor Main, Des Moines, IA 50314 in Polk County. The practice phone is (515) 247-4400.

Dr. Deming's primary practice is Select Specialty Hospital - Des Moines in Des Moines, Iowa, part of Select Medical Holdings. Dr. Deming is also affiliated with MercyOne Des Moines Medical Center. The medical group on file is MercyOne Clive Family Medicine. Dmand AI also links Dr. Deming to 1 more group practice or clinic, named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Deming practices, 3 sites in all. Vendor and product names are available with a free account.

Radiation oncology is Dr. Deming's primary specialty in the NPI Registry, under taxonomy code 2085R0001X. Dr. Deming is board certified in radiation oncology by the American Board of Radiology. Dmand AI has Dr. Deming's licenses on file in 2 states: Iowa and California.

CMS data shows 549 Medicare services from Dr. Deming across 7 procedure codes in 2024, for 355 Medicare patients. Medicare paid $39,796 for them. Every service was in an office.

CMS counts 355 Medicare patients who saw Dr. Deming in 2024. The largest group is 65 to 74, with 204 patients. 75% of them have cancer, and 72% have high cholesterol. Their average risk score is 1.47, where 1.00 is the Medicare average.

Across all payers, Dmand AI patient panel data puts Dr. Deming's median patient age at 66, with 59% women.

In 2024, Dr. Deming wrote 156 Medicare Part D claims for 38 patients. 96% of them were for generic drugs. CMS names the drug for 96 of them, across 5 drugs with 11 or more claims each, at $1,855 in total drug cost. In 2023, CMS named 110 claims across 3 drugs.

Dr. Deming accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Dr. Deming as offering telehealth.

Dmand AI links 15 papers to Dr. Deming, published from 2012 to 2021. 2016 was the busiest year, with 2. The most frequent topics are Hodgkin Disease, Diagnostic Imaging and Lung Neoplasms. Dr. Deming has published most often in Radiology. Dr. Deming's most frequent co-authors are Jean M. Connors, MD, Daniel E. Dosoretz, MD and John H. Glick, MD.

Dmand AI links Dr. Deming to 25 clinical trials, 10 of them phase 3 studies. 16 are still active or recruiting. Conditions studied include Lung Neoplasms, Thoracic Neoplasms and Brain Neoplasms. National Cancer Institute (NCI) sponsors the most, 15.

CMS Open Payments shows 35 general payments to Dr. Deming from 19 drug and device companies from 2016 to 2025. Food and beverage make up the largest share, 99% of the total. AstraZeneca Pharmaceuticals LP paid the most, $554.

Dr. Deming graduated from Creighton University School of Medicine - Omaha in 1980. Dr. Deming is a member of ASCO.

Dr. Deming is in network with 14 carriers, including Aetna, Elevance and Blue Cross Blue Shield of Michigan. PPO plans come from the most carriers, 9. Check the plan with the practice before a visit.